AstraZeneca’s MedImmune spins out biotech to focus on autoimmune candidates

This article was originally published here

MedImmune, the global biologics research and development arm of AstraZeneca, is creating a stand-alone company for early-stage inflammation and autoimmunity biologics.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply